Abeona Therapeutics Total Assets Growth & History (ABEO)
Abeona Therapeutics's total assets was $219.6M for fiscal 2025.
View full Abeona Therapeutics company overviewAbeona Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $219.6M | $110.6M | +101.57% |
| 2024 | 2024-12-31 | $108.9M | $44.9M | +70.20% |
| 2023 | 2023-12-31 | $64.0M | −$212,000 | −0.33% |
| 2022 | 2022-12-31 | $64.2M | −$15.4M | −19.31% |
| 2021 | 2021-12-31 | $79.6M | −$71.6M | −47.36% |
| 2020 | 2020-12-31 | $151.2M | −$72.2M | −32.31% |
| 2019 | 2019-12-31 | $223.4M | $49.0M | +28.09% |
| 2018 | 2018-12-31 | $174.4M | −$4.4M | −2.44% |
| 2017 | 2017-12-31 | $178.8M | $67.7M | +60.97% |
| 2016 | 2016-12-31 | $111.1M | $31.0M | +38.73% |
| 2015 | 2015-12-31 | $80.1M | $63.5M | +382.78% |
| 2014 | 2014-12-31 | $16.6M | $16.0M | +2605.06% |
| 2013 | 2013-12-31 | $613,000 | −$1.1M | −64.57% |
| 2012 | 2012-12-31 | $1.7M | −$2.1M | −54.29% |
| 2011 | 2011-12-31 | $3.8M | −$5.0M | −56.85% |
| 2010 | 2010-12-31 | $8.8M | — | — |
Abeona Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $179.5M | −$66.7M | −27.10% |
| Q1 2026 | 2026-03-31 | $198.5M | $99.1M | +99.76% |
| Q4 2025 | 2025-12-31 | $219.6M | $110.6M | +101.57% |
| Q3 2025 | 2025-09-30 | $231.1M | $110.5M | +91.63% |
| Q2 2025 | 2025-06-30 | $246.2M | $112.2M | +83.75% |
| Q1 2025 | 2025-03-31 | $99.4M | $24.5M | +32.79% |
| Q4 2024 | 2024-12-31 | $108.9M | $44.9M | +70.20% |
| Q3 2024 | 2024-09-30 | $120.6M | $54.5M | +82.47% |
| Q2 2024 | 2024-06-30 | $134.0M | $80.5M | +150.24% |
| Q1 2024 | 2024-03-31 | $74.8M | $21.5M | +40.27% |
| Q4 2023 | 2023-12-31 | $64.0M | −$212,000 | −0.33% |
| Q3 2023 | 2023-09-30 | $66.1M | $27.3M | +70.50% |
| Q2 2023 | 2023-06-30 | $53.5M | $8.8M | +19.75% |
| Q1 2023 | 2023-03-31 | $53.3M | −$1.8M | −3.31% |
| Q4 2022 | 2022-12-31 | $64.2M | −$15.4M | −19.31% |
| Q3 2022 | 2022-09-30 | $38.8M | −$80.3M | −67.43% |
| Q2 2022 | 2022-06-30 | $44.7M | −$86.0M | −65.78% |
| Q1 2022 | 2022-03-31 | $55.2M | −$86.3M | −60.99% |
| Q4 2021 | 2021-12-31 | $79.6M | −$71.6M | −47.36% |
| Q3 2021 | 2021-09-30 | $119.0M | −$40.3M | −25.32% |
| Q2 2021 | 2021-06-30 | $130.7M | −$33.7M | −20.50% |
| Q1 2021 | 2021-03-31 | $141.4M | −$33.6M | −19.18% |
| Q4 2020 | 2020-12-31 | $151.2M | −$72.2M | −32.31% |
| Q3 2020 | 2020-09-30 | $159.4M | $16.6M | +11.62% |
| Q2 2020 | 2020-06-30 | $164.4M | $5.0M | +3.12% |
| Q1 2020 | 2020-03-31 | $175.0M | $8.9M | +5.34% |
| Q4 2019 | 2019-12-31 | $223.4M | $49.0M | +28.09% |
| Q3 2019 | 2019-09-30 | $142.8M | −$17.8M | −11.09% |
| Q2 2019 | 2019-06-30 | $159.4M | −$7.3M | −4.37% |
| Q1 2019 | 2019-03-31 | $166.1M | −$9.5M | −5.42% |
| Q4 2018 | 2018-12-31 | $174.4M | −$4.4M | −2.44% |
| Q3 2018 | 2018-09-30 | $160.6M | $64.8M | +67.74% |
| Q2 2018 | 2018-06-30 | $166.7M | $70.0M | +72.46% |
| Q1 2018 | 2018-03-31 | $175.7M | $70.4M | +66.84% |
| Q4 2017 | 2017-12-31 | $178.8M | $67.7M | +60.97% |
| Q3 2017 | 2017-09-30 | $95.7M | $21.9M | +29.69% |
| Q2 2017 | 2017-06-30 | $96.7M | $22.5M | +30.35% |
| Q1 2017 | 2017-03-31 | $105.3M | $27.9M | +35.99% |
| Q4 2016 | 2016-12-31 | $111.1M | $31.0M | +38.73% |
| Q3 2016 | 2016-09-30 | $73.8M | −$15.7M | −17.57% |
| Q2 2016 | 2016-06-30 | $74.2M | −$2.8M | −3.60% |
| Q1 2016 | 2016-03-31 | $77.4M | $64.3M | +490.23% |
| Q4 2015 | 2015-12-31 | $80.1M | $63.5M | +382.78% |
| Q3 2015 | 2015-09-30 | $89.5M | $89.3M | +31881.79% |
| Q2 2015 | 2015-06-30 | $76.9M | $76.7M | +31952.08% |
| Q1 2015 | 2015-03-31 | $13.1M | $12.6M | +2644.14% |
| Q4 2014 | 2014-12-31 | $16.6M | $16.0M | +2605.06% |
| Q3 2014 | 2014-09-30 | $280,000 | −$812,000 | −74.36% |
| Q2 2014 | 2014-06-30 | $240,000 | −$2.2M | −89.99% |
| Q1 2014 | 2014-03-31 | $478,000 | −$1.2M | −72.23% |
| Q4 2013 | 2013-12-31 | $613,000 | −$1.1M | −64.57% |
| Q3 2013 | 2013-09-30 | $1.1M | −$142,000 | −11.51% |
| Q2 2013 | 2013-06-30 | $2.4M | −$40,000 | −1.64% |
| Q1 2013 | 2013-03-31 | $1.7M | −$1.5M | −46.15% |
| Q4 2012 | 2012-12-31 | $1.7M | −$2.1M | −54.29% |
| Q3 2012 | 2012-09-30 | $1.2M | −$986,000 | −44.41% |
| Q2 2012 | 2012-06-30 | $2.4M | −$2.6M | −51.89% |
| Q1 2012 | 2012-03-31 | $3.2M | — | — |
| Q4 2011 | 2011-12-31 | $3.8M | −$5.0M | −56.85% |
| Q3 2011 | 2011-09-30 | $2.2M | — | — |
| Q2 2011 | 2011-06-30 | $5.1M | — | — |
| Q4 2010 | 2010-12-31 | $8.8M | — | — |
Abeona Therapeutics total assets trends
Over the last five fiscal years, Abeona Therapeutics's total assets increased from $151.2M to $219.6M, a change of $68.4M. The latest reported quarter, Q2 2026, shows $179.5M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abeona Therapeutics source filings ↗